These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32428800)

  • 21. Prognostic Significance of the Maximum Standardized Uptake Value on the Prognosis of Clinical Stage IA Lung Adenocarcinoma Based on the 8th Edition TNM Classification.
    Shigefuku S; Ito H; Miura J; Kikuchi A; Isaka T; Adachi H; Nakayama H; Ikeda N
    Ann Surg Oncol; 2023 Feb; 30(2):830-838. PubMed ID: 36282457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer.
    Yuan R; Yamada A; Weber B; Ho C
    J Neurooncol; 2016 May; 127(3):525-33. PubMed ID: 26780337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment.
    Koul R; Rathod S; Dubey A; Bashir B; Chowdhury A
    Lung Cancer; 2018 Sep; 123():116-120. PubMed ID: 30089581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma.
    Renaud S; Seitlinger J; Guerrera F; Reeb J; Beau-Faller M; Voegeli AC; Siat J; Clément-Duchêne C; Tiotiu A; Santelmo N; Costardi L; Ruffini E; Falcoz PE; Vignaud JM; Massard G
    Ann Surg Oncol; 2018 Apr; 25(4):1069-1078. PubMed ID: 29362963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Correlation Analysis of Ki67 Expression and EGFR Mutation on the Risk of Recurrence and Metastasis in Postoperative Patients with Stage I Lung Adenocarcinoma].
    Xu L; Guo R
    Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):852-861. PubMed ID: 36617471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
    Jiao XD; Qin BD; You P; Cai J; Zang YS
    Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of the Eighth Edition TNM Lung Cancer Staging System.
    Hwang JK; Page BJ; Flynn D; Passmore L; McCaul E; Brady J; Yang IA; Marshall H; Windsor M; Bowman RV; Naidoo R; Guan T; Philpot S; Blake ME; Fong KM
    J Thorac Oncol; 2020 Apr; 15(4):649-654. PubMed ID: 31863848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
    Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
    Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer.
    Zhu WY; Hu XF; Fang KX; Kong QQ; Cui R; Li HF; He JY; Zhang YK; Le HB
    Histol Histopathol; 2019 Nov; 34(11):1269-1278. PubMed ID: 31062864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
    Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
    Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
    Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
    Kitagawa S; Zenke Y; Taki T; Aokage K; Sakai T; Shibata Y; Izumi H; Nosaki K; Umemura S; Matsumoto S; Yoh K; Sakamoto N; Sakashita S; Kojima M; Tsuboi M; Goto K; Ishii G
    Lung Cancer; 2024 Feb; 188():107453. PubMed ID: 38160515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Predictive role of EGFR mutation status on postoperative prognosis in patients with resected lung adenocarcinomas].
    Dong Y; Li Y; Peng H; Jin B; Huang A; Bai H; Xiong H; Han B
    Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):177-83. PubMed ID: 23601297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.
    Wang J; Liu Z; Pang Q; Zhang T; Chen X; Er P; Wang Y; Wang P; Wang J
    BMC Cancer; 2020 Sep; 20(1):837. PubMed ID: 32883221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis.
    Isaka T; Ito H; Nakayama H; Yokose T; Katayama K; Yamada K; Masuda M
    Mol Diagn Ther; 2019 Oct; 23(5):657-665. PubMed ID: 31347029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.
    Jiang R; Wang X; Li K
    Oncotarget; 2016 May; 7(18):26823-36. PubMed ID: 27072585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
    Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
    BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
    Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
    BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis.
    Zhang Z; Wang T; Zhang J; Cai X; Pan C; Long Y; Chen J; Zhou C; Yin X
    PLoS One; 2014; 9(8):e106053. PubMed ID: 25162713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.